Association of peripheral insulin resistance and other markers of type 2 diabetes mellitus with brain amyloid deposition in healthy individuals at risk of dementia

Manuscript Number: 

20-0145R2

Author(s): 
Anette Hall, Nina Kemppainen, Miia Kivipelto, Francesca Mangialasche, Patrizia Mecocci, Tiia Ngandu, Timo Pekkala, Juha O. Rinne, Hilkka Soininen, Alina Solomon, Jaakko Tuomilehto

Disclosures

Anette Hall

  • Nothing to Disclose

Nina Kemppainen

  • Nothing to Disclose

Miia Kivipelto

  • Consulting Fees:
    Combinostics, Biogen
    Grants
    • Agency: 
      Janssen
      Dates: 
      2020

Francesca Mangialasche

  • Nothing to Disclose

Patrizia Mecocci

  • Nothing to Disclose

Tiia Ngandu

  • Nothing to Disclose

Timo Pekkala

  • Equity:
    Small positions in publicly traded companies that do not operate in the health care or pharmaceuticals sectors. (Amazon, Alphabet, Twitter, Shell, Sampo, Berkshire).

Juha O. Rinne

  • Nothing to Disclose

Hilkka Soininen

  • Consulting Fees:
    Fees for advisory boards from ACImmune and Novo Nordisk.

Alina Solomon

  • Nothing to Disclose

Jaakko Tuomilehto

  • Consulting Fees:
    Eli Lilly, Glucolife, Merck, Novo Nordisk
    Equity:
    Glucolife, Orion pharma
    Lecture Fees:
    Merck, Eli Lilly
    Grants
    • Agency: 
      Boehringer Ingelheim
      Dates: 
      1.1.2013-31.12.2018